Department of Medicine 5 – Haematology and Oncology

Krüppel-like factor 2 controls IgA plasma cell compartmentalization and IgA responses (2022) Wittner J, Schulz S, Steinmetz T, Berges J, Hauke M, Channell WM, Cunningham AF, et al. Journal article Physiological levels of 25-hydroxyvitamin D3 induce a suppressive CD4+ T cell phenotype not reflected in the epigenetic landscape (2022) Matos C, Renner K, Peuker A, Schoenhammer G, Schreiber L, Bruss C, Eder R, et al. Journal article Impact of spatially heterogeneous trop‐2 expression on prognosis in oral squamous cell carcinoma (2022) Erber R, Spoerl S, Mamilos A, Krupar R, Hartmann A, Rübner M, Taxis J, et al. Journal article Neutrophil extracellular traps drive epithelial‐mesenchymal transition of human colon cancer (2021) Stehr A, Wang G, Demmler R, Stemmler M, Straube J, Tripal P, Schmid B, et al. Journal article, Original article CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma (2021) Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, et al. Journal article Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative (2021) Kayser S, Schlenk RF, Lebon D, Carre M, Goetze KS, Stoelzel F, Berceanu A, et al. Journal article BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+advanced solid tumors (2021) Haanen J, Mackensen A, Koenecke C, Alsdorf W, Desuki A, Wagner-Drouet E, Heudobler D, et al. Conference contribution An easily expandable multi-drug LC-MS assay for the simultaneous quantification of 57 oral antitumor drugs in human plasma (2021) Kehl N, Schlichtig K, Dürr P, Bellut L, Dörje F, Fietkau R, Pavel ME, et al. Journal article Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease: M. G. Zewde et al (2021) Zewde MG, Morales G, Gandhi I, Özbek U, Aguayo-Hiraldo P, Ayuk F, Baez J, et al. Journal article Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML (2021) Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Sauer T, Crysandt M, et al. Journal article